The use of human intravenous immunoglobulin (hIVIG) in cases of canine primary immune-mediated hemolytic anemia (IMHA) has been previously described, but investigations have been limited by cost and availability. The aim of this study was to investigate the administration of high-dose IgM-enriched hIVIG (Pentaglobin®) at the time of diagnosis of canine primary IMHA.
Dogs diagnosed with primary IMHA at UK specialty hospitals were prospectively enrolled. All dogs received prednisolone or dexamethasone alongside clopidogrel. Patients were randomized to receive Pentaglobin® at 1g/kg on up to two occasions, or a control group. No additional immunosuppressive drugs were allowed within the first 7 days of treatment and other supportive treatments were given at the discretion of the attending clinician. Remission was defined as a stable PCV for 24 hours.
Ten of 11 dogs from the treatment group and 2 of 3 dogs from the control group achieved remission and survived to hospital discharge. Survival and time to remission were not significantly different between groups. The volume of packed red blood cells transfused, normalized for body weight, was not significantly different between groups. Potential adverse reactions to Pentaglobin® occurred in two patients but clinical signs may have been related to the patients’ underlying disease.
Treatment with high-dose Pentaglobin® was well tolerated by patients but no significant advantage was found in this small study. Larger studies are warranted to identify any potential benefits.
Internal Medicine Resident
Animal Health Trust
I graduated from Nottingham Vet School (UK) in 2012 and spent three years in Small Animal General Practice. In 2015, I undertook a Rotating Internship at the Animal Health Trust (Newmarket, UK) and subsequently started a Residency in Internal Medicine, in 2016, at the same institution.
Friday, June 15
8:15 AM – 8:30 AM
The asset you are trying to access is locked. Please enter your access key to unlock.